Summary:
Public health data show designer synthetic drugs and drug combinations are adding a whole new set of health risks for users. Discussion topics include: These novel psychoactive substances (NPS) could impact your screening and management efforts for your patients.1
As part of our support for you and your patients, we’ve been working to identify and track the constantly evolving NPS, and we invite you to see what we’ve learned by watching our new webinar, presented by Dr Jack Kain, Director, Medical Science Liaison, Drug Monitoring & Toxicology, and Jason Suomala, Product Director, Drug Monitoring & Toxicology.
Over 13% of samples already tested for traditional drugs of abuse were retested and found positive for novel psychoactive substances, including xylazine, designer fentanyl analogs, and designer benzodiazepines.2
In an analysis of 3,734 randomly selected, anonymized remnant specimens that had already undergone routine drug screening, 1 in 8 samples revealed a previously undetected novel psychoactive substance.2
Discussion topics include:
- Overview of the various classes of new designer substances appearing across the US
- Prevalence data pulled from recent laboratory testing
- Review of available testing options to identify NPS use and/or exposure
Learning Objectives:
- Increase your knowledge about novel Psychoactive substances (NPS), and why you should be
concerned
- Gain a deeper understanding of increasing NPS prevalence and characteristics of specific NPS
classes and drugs
- Determine clinical utility of NPS testing and share test results from an NPS case study
Presenters:
- Jason Suomala, Product Director, Drug Monitoring & Toxicology
- Dr. Jack Kain, Director, Medical Science Liasion, Drug Monitoring & Toxicology
Time of talk: 30.47 minutes
Posted as on-demand webinar: February 7, 2025
Disclosure: The views and opinions are those of the presenter. The content was current as of the time of recording in 2025.
Your Privacy Choices